Craig Frankil, DO
Interventional Cardiology · Philadelphia, PANPI 1942231709
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,815 of the $58,675 with a category attached, or 81.5%. 27 manufacturers reported payments, led by Johnson & Johnson at 48.1% of the total. Reporting peaked in 2019 at $25,722 and has fallen 99.6% since, to $97 in 2025.
Across 225 payments — averaging $260.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$28K
- AstraZeneca$25K
- Cardiovascular Systems Inc.$1K
- Boston Scientific$707
- Silk Road Medical, Inc.$479
- Impulse Dynamics (USA) Inc.$465
- plus $2K from 21 others
Across 12 payments — averaging $4594.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$24K
- AstraZeneca$21K
- Abbott$9K
What the payments were for
- Consulting fees$3,2556%
- Speaking & faculty fees$47,81581%
- Travel & lodging$6971%
- Food & beverage$6,90712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 53 | $28,222 |
| AstraZeneca | 27 | $25,329 |
| Cardiovascular Systems Inc. | 15 | $1,019 |
| Boston Scientific | 30 | $707 |
| Silk Road Medical, Inc. | 3 | $479 |
| Impulse Dynamics (USA) Inc. | 6 | $465 |
| Cook Medical LLC | 11 | $417 |
| Novartis | 33 | $402 |
| Veryan Medical Incorporated | 1 | $303 |
| Bard Peripheral Vascular, Inc. | 3 | $275 |
| Amgen | 9 | $245 |
| Shockwave Medical, Inc | 3 | $229 |
| Boehringer Ingelheim | 6 | $109 |
| Kiniksa Pharmaceuticals, Ltd. | 6 | $102 |
| Lexicon Pharmaceuticals, Inc. | 4 | $88 |
| Akcea Therapeutics, Inc. | 3 | $63 |
| Pfizer | 2 | $29 |
| Abiomed | 1 | $27 |
| Cardiva Medical, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $23 |
| Edwards Lifesciences | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Medicomp Inc | 1 | $18 |
| Bayer | 1 | $18 |
| Watermark Medical, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$27,400
- BRILINTA$24,060
- OPTIMIZER$555
- ENROUTE Transcarotid Stent$479
- ENROUTE Transcarotid Neuroprotection System$479
- Coronary Orbital Atherectomy System$474
- ENHANCE Transcarotid Peripheral Access Kit$309
- ENROUTE .014 Guidewire$309
- BioMimics 3D Vascular Stent System$303
- Cook Medical Zilver PTX$124
- Vascular Lithotripsy$121
- Cook Medical Self-Expanding Stent$102
How this compares
$58,675 in reported general payments places this provider in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 223 | $224,684 |
| EliquisApixaban | 101 | $127,936 |
| EntrestoSacubitril/Valsartan | 88 | $85,930 |
| Repatha SureclickEvolocumab | 31 | $28,076 |
| BrilintaTicagrelor | 23 | $17,645 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 115 | $5,325 |
| Metoprolol Succinate | 295 | $4,981 |
| Valsartan | 77 | $4,384 |
| Atorvastatin Calcium | 226 | $2,728 |
| Nebivolol Hcl | 46 | $2,661 |
| Rosuvastatin Calcium | 131 | $1,961 |
| ClopidogrelClopidogrel Bisulfate | 131 | $1,763 |
| Clonidine | 17 | $1,441 |
| Cilostazol | 31 | $1,342 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 29 | $1,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $28,222 | $224,684223 claims |
| PfizerEliquis | $29 | $127,936101 claims |
| NovartisEntresto | $402 | $85,93088 claims |
| AstraZenecaBrilinta | $25,329 | $17,64523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Philadelphia
- Jon GeorgePhiladelphia$637K
- Sanjog KalraPhiladelphia$444K
- Taisei KobayashiPhiladelphia$384K
- Howard HerrmannPhiladelphia$259K
- Jay GiriPhiladelphia$157K
- Paul FiorilliPhiladelphia$104K
- Nicholas RuggieroPhiladelphia$74K
- Michael BodePhiladelphia$58K
- Oleg VishnevskyPhiladelphia$49K
- Ashwin NathanPhiladelphia$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.